Followers | 13 |
Posts | 596 |
Boards Moderated | 0 |
Alias Born | 01/05/2013 |
![](https://investorshub.advfn.com/uicon/375958.png?cb=1498748508)
Tuesday, April 22, 2014 10:30:51 PM
This is one of the many highlights.
MJFF on the Eltoprazine Data
“Dyskinesia is a top priority for the Foundation because of its impact on the quality of life of people living with Parkinson’s disease,”
“The results show early promise in finding a potential treatment for dyskinesia, and we look forward to working with this team to drive their program forward.”
Todd Sherer, PhD, CEO of The Michael J. Fox Foundation.
http://content.stockpr.com/amarantus/media/3b975cd360749a34eb202bd4c0121792.pdf
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM